PICSO Impulse System Four Month Follow-Up Shows Infarct Size-Reduction
January 31, 2014
Coronary sinus pressure increase during two cycles of PICSO (clinical data from the Prepare PICSO study).
January 31, 2014 — Miracor Medical Systems completed four months’ follow-up of patients enrolled in the “Prepare RAMSES” clinical trial of PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) System. PICSO is designed to improve myocardial perfusion following primary PCI (Percutaneous Coronary Intervention, or angioplasty). Interim data from early results indicate a strong trend towards a larger reduction in infarct for patients receiving the PICSO therapy in complement with primary PCI. A total of 30 patients have successfully enrolled in the clinical trial, with no device-related adverse events.
The study is underway in several European centers with Principal Investigator Jan J. Piek, M.D., Ph.D., professor of interventional cardiology and director of the Heart Centre, Academic Medical Centre, University of Amsterdam. Miracor Medical is expanding PICSO’s CE marking throughout Europe.
The Miracor PICSO Impulse System is designed to treat acute heart attack STEMI (ST-segment elevation myocardial infarction) patients in complement to coronary angioplasty.
For more information: www.miracormedical.com
More like this
- New Study Shows Miracor’s PICSO System Improves Myocardial Perfusion
- Balloon Catheter System for Coronary Revascularization Receives CE Mark
- Miracor Secures Financing To Commercialize Device to Limit Reperfusion Injury
- Miracor Reports First-In-Man Results Using Its PICSO System to Treat AMI
- Pilot Study for ACS Revascularization System Completed